4//SEC Filing
LINDSAY RICHARD P 4
Accession 0001209191-08-043641
CIK 0000821616other
Filed
Jul 23, 8:00 PM ET
Accepted
Jul 24, 5:19 PM ET
Size
20.6 KB
Accession
0001209191-08-043641
Insider Transaction Report
Form 4
LINDSAY RICHARD P
VP and CFO
Transactions
- Disposition to Issuer
Option (Right to Buy)
2008-07-22−33,334→ 0 totalExercise: $11.05From: 2008-07-22Exp: 2016-09-11→ Common Stock, $0.02 par value (33,334 underlying) - Disposition to Issuer
Common Stock, $0.02 par value
2008-07-22$14.82/sh−2,846$42,168→ 0 total(indirect: By 401(k)) - Disposition to Issuer
Option (Right to Buy)
2008-07-22−16,666→ 0 totalExercise: $11.05From: 2007-09-11Exp: 2016-09-11→ Common Stock, $0.02 par value (16,666 underlying) - Disposition to Issuer
Restricted Stock Units
2008-07-22−6,750→ 0 totalFrom: 2008-07-22→ Common Stock, $0.02 par value (6,750 underlying) - Disposition to Issuer
Common Stock, $0.02 par value
2008-07-22$14.82/sh−2,250$33,337→ 0 total
Footnotes (8)
- [F1]Disposed of in connection with the merger of Beryllium Merger Corporation ("Acquisition Sub") with and into Bentley Pharmaceuticals, Inc. ("Bentley"), effective July 22, 2008 (the "Effective Time"), (the "Merger"), pursuant to the Agreement and Plan of Merger, dated as of March 31, 2008, by and among Bentley, Teva Pharmaceutical Industries, Ltd. and Acquisition Sub (the "Merger Agreement"). In connection with the Merger, each share of Common Stock listed in Table I was exchanged for the right to receive $14.8165, per share in cash.
- [F2]This option was cancelled in the Merger in exchange for a cash payment of $62,827.49, representing the difference between the exercise price of the option and the merger consideration per share ($14.8165) multiplied by the total number of shares of Common Stock underlying the option.
- [F3]This option was cancelled in the Merger in exchange for a cash payment of $63,820.78, representing the difference between the exercise price of the option and the merger consideration per share ($14.8165) multiplied by the total number of shares of Common Stock underlying the option.
- [F4]Pursuant to the terms of the Merger Agreement, all options, whether or not exercisable or vested at the Effective Time, became, as of the Effective Time fully vested and exercisable.
- [F5]This option was cancelled in the Merger in exchange for a cash payment of $125,662.51, representing the difference between the exercise price of the option and the merger consideration per share ($14.8165) multiplied by the total number of shares of Common Stock underlying the option.
- [F6]This option was cancelled in the Merger in exchange for a cash payment of $127,649.22, representing the difference between the exercise price of the option and the merger consideration per share ($14.8165) multiplied by the total number of shares of Common Stock underlying the option.
- [F7]In connection with the Merger, each Restricted Stock Unit was converted into the right to receive $14.8165 per share in cash.
- [F8]Restricted Stock Units were granted under the terms of the Company's Amended and Restated 2005 Equity and Incentive Plan. Pursuant to the terms of the Merger Agreement, all restricted stock units, whether or not vested at the Effective Time, became, as of the Effective Time fully vested.
Documents
Issuer
BENTLEY PHARMACEUTICALS INC
CIK 0000821616
Entity typeother
IncorporatedMA
Related Parties
1- filerCIK 0001206508
Filing Metadata
- Form type
- 4
- Filed
- Jul 23, 8:00 PM ET
- Accepted
- Jul 24, 5:19 PM ET
- Size
- 20.6 KB